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Background: Although the Centres for disease Control and Prevention (CDC) recommends empiric treatment for
schistosomiasis and strongyloidiasis (prevalent but treatable parasitic infections) in some refugee groups it is unclear
if these guidelines should be extended to non-refugee immigrants from endemic areas. We aimed to assess
seroprevalence of, and risk factors for, positive schistosomiasis and strongyloides serology in HIV-infected patients
from endemic areas attending a European Infectious Diseases clinic.
Methods: In a prospective cohort study, HIV-infected patients from helminth endemic areas underwent clinical
assessment and blood draw for schistosomiasis and strongyloides serology, routine haematology and inflammatory
markers (ESR and CRP). Between-group differences were analyzed by Wilcoxin Signed Rank and Fisher’s t tests as
appropriate.
Results: Ninety HIV-infected patients (mean [standard deviation (SD)] age 34 [6] years, 29% male) were recruited
from May 2008 to June 2009. Nine (10%) subjects tested positive for helminth infections. Seven tested positive for
schistosomiasis (8%) while two tested positive for strongyloides (2%). Seropositive subjects were more likely to have
higher eosinophil counts (mean [SD]) (0.3 [0.3] vs. 0.15 [0.2] x103cells/cm, P = 0.021) with a trend towards lower
CD4+ T-cell counts (mean [SD]) (280 [218] vs. 395 [217] cells/mm3, P = 0.08).
Conclusion: The high prevalence of helminth infections (10%) in asymptomatic HIV infected adults identified in this
study supports routine screening of immigrants from helminth endemic areas or with exposure history.
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Worldwide over 200 million people are infected with
Schistosoma species [1] while up to 100 million are
infected with Strongyloides stercoralis [2]. Areas of highest
endemicity include sub-Saharan Africa, eastern South
America and regions of Asia. Untreated, both parasites
can persist for years to decades and cause significant mor-
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reproduction in any medium, provided the orA significant proportion of individuals accessing HIV
care in Europe originate from areas endemic for hel-
minth infections. Almost one third of persons accessing
HIV care in Ireland are of African origin (personal com-
munication, Dr Helen Tuite). These individuals have ex-
posure risk to schistosomiasis, strongyloides and other
parasitic infections. Limited data exists on the preva-
lence of helminth infections in HIV-infected immigrants.
European have studies reported a prevalence of schisto-
somiasis ranging from 11% to 16% and prevalence of
strongyloides ranging from 2% to 11% [3-5] in HIV
infected immigrants while studies in the United States
have reported a prevalence of between 3% and 29% forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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loides in HIV infected immigrants[6,7].
Schistosomiasis or bilharzia is caused by a fluke worm
of the genus Schistosoma. Adult worms can live for de-
cades in the human host releasing ova causing inflam-
matory and obstructive disease in the urinary system (S
haematobium), intestinal disease, hepatosplenic inflam-
mation, and liver fibrosis (S mansoni, S japonicum) [8].
Immigrants from endemic areas can remain infected for
30 to 40 years [9]. A single dose of praziquantel reliably
cures 60 to 90 percent of infected patients and substan-
tially decreases worm burden and egg production in
those who are not cured [10].
Strongyloidiasis is caused by infection with Strongy-
loides stercoralis filariform larvae found in soil. Adult
worms burrow into the mucosa of the duodenum and je-
junum and have a unique capability to replicate inside
the host allowing chronic infection to persist for many
years and the potential for uncontrolled multiplication.
This can result in life-threatening dissemination of
larvae in individuals, particularly those with immuno-
deficiency [11].
Clinical presentations of strongyloidiasis are varied ran-
ging from asymptomatic eosinophilia to hyper-infection
with disseminated disease and septic shock in immuno-
compromised individuals [12,13]. S. stercoralis hyper-
infection has been described in HIV infected patients as
part of the immune reconstitution inflammatory syn-
drome after starting highly active antiretroviral therapy
(HAART) [14,15]. The recommended treatment for stron-
gyloidiasis is ivermectin [16].
The Centers for Disease Control and Prevention
(CDC) have published guidelines for screening of refu-
gees for parasitic infections [17] however there are no
standards for how or when to look for parasitic infec-
tions among non-refugee immigrants from endemic
areas that may be resident in a developed country for ex-
tended periods. Furthermore there are no guidelines for
assessing those from “parasite endemic” regions that are
infected with HIV.
The primary objective of this study was to determine
the seroprevalence of schistosomiasis and strongyloides
among HIV-infected persons that have immigrated to
Ireland from “parasite endemic” countries. The second-
ary objective was to evaluate whether specific symptoms,
signs or laboratory parameters are useful in predicting
parasitic infection.
Methods
The Helminth Prevalence Study was a prospective single
visit cohort study carried out in the Infectious Diseases
clinic at the Mater Misericordiae University Hospital
(MMUH) in Dublin from June 2008-June 2009. MMUH
is a tertiary referral teaching hospital in a sociallydeprived area of Dublin and serves a catchment of
185,000 patients.
Consecutive HIV-infected patients from countries of
endemic helminth infection were recruited. Patients were
screened for the presence of schistosomal and strongyloides
antibodies in serum samples using an enzyme-linked
immunosorbent assay (ELISA).
The schistosomiasis ELISA used was a schistosomal
egg antigen “in house” assay which detects immunoglobulin
G antibodies to both S. mansoni and S. haematobium with
high sensitivity and specificity and minimal cross-reactivity.
This ELISA is reported to detect 96% of Schistosoma
mansoni and 92% of Schistosoma haematobium infections
however, the test does not distinguish active from treated
infections [18].
The strongyloides assay used (Bordier Affinity Prod-
ucts SA, Switzerland) detects strongyloides ratti somatic
larval antigens. Diagnostic accuracy for strongyloides
serology has a reported sensitivity of 88%, specificity of
94% and cross reactivity of 77% with other parasitosis,
mostly helminthiasis [19,20]. Serological assays were
performed at the Hospital for Tropical Diseases, London,
the national reference laboratory in the United Kingdom.
Demographic data recorded for all patients included
age, gender, country of birth, reason for travel to Ireland,
length of stay in Ireland, presence of disease-specific
symptoms [21,22], previous diagnosis and treatment of
helminth infection and use of HAART. Along with
helminth serology, full blood count with differential, C-
reactive protein (CRP), erythrocyte sedimentation rate
(ESR), lymphocyte subsets and HIV RNA were recorded.
Treatment outcomes and direct stool or urine analysis
for parasitic infections were not recorded as this was a
single visit study. The patients overseeing health care
providers were informed of positive serology and, where
necessary, arranged further diagnostics, treatment and
follow up.
Data were entered onto study specific case report
forms and then transferred to a study specific data base.
Continuous variables were analysed using Wilcoxon
Signed Rank test and discrete variables by Fisher’s t test
as appropriate. All analyses were performed using PASW
statistics, version 18 (SPSS, NYC). The study was ap-
proved by the local Research Ethics Committee and all
patients provided written, informed consent.
Results
Baseline demographic and disease characteristics are
outlined in Table 1. Ninety HIV-infected patients were
recruited and tested for the presence of schistosomal and
strongyloides antibodies. Mean [SD] age was 34 [6] years.
Twenty six (29%) patients were male. Twenty six percent,
31% and 34% were from South, East and West Africa
respectively. Sixty eight percent of patients recruited had
Table 1 Demographics and baseline characteristics of study cohort
Cohort Helminth positive P value
Y N (univariate)
N,% 90 9 10% 81 90% -
Age, years (mean) [CI] 34 [33–36] 36 [33–39] 34 [33–35] 0.328
Male (N,%) 26 29% 5 56% 21 26% 0.11
Region of Birth (N,%)
- South Africa 23 26% 4 44% 19 23%
- East Africa 28 31% 3 33% 25 31%
- West Africa 31 34% 2 22% 29 36%
- Central Africa 6 7% 0 0% 6 7%
- Non-Africa 2 2% 0 0% 2 2% 0.603
Years in Ireland (mean) [SD] 5 [3] 5 [3] 4 [3] 0.59
HIV RNA (median [IQR] (copies/ml)) (n = 89) 50 [1718] 50 [2644] 50 [329779] 0.2
CD4+ T-cell count (mean [CI] (cells/mm3)) 398 [345–452] 280 [218] 395 [217] 0.08
Reason for travel to Ireland (N,%)
- Asylum 61 68% 7 78% 54 67%
- Education 23 26% 1 11% 22 27%
- Other 6 7% 1 11% 5 6% 0.53
Previous schistosomiasis therapy (N,%) 6 6.7% 1 1% 5 6% 0.57
Previous strongyloides therapy (N,%) 2 2.2% 1 1% 1 1% 0.15
Eosionophils (x103cells/mm3) (mean [CI]) 0.16 [0.11-0.2] 0.30 [0.30] 0.15 [0.16] 0.021
Hemoglobin (g/dL) (mean [CI]) 12 [12–13] 13 [1] 12 [1] 0.28
MCV (fL) (mean [CI]) 84 [82–87] 84 [7] 85 [11] 0.86
CRP (mg/l) (mean [CI]) (n = 79) 5 [3–5] 7(n = 9) [4] 5(n = 70) [5] 0.25
ESR (mm/hr) (mean [CI]) (n = 63) 29 [22–37] 22(n = 7) [28] 31(n = 61) [28] 0.43
WBC (x109/L) (mean [CI]) 5 [4–5] 4 [1] 5 [1] 0.89
Lymphocytes (x109/L) (mean [CI]) 2 [1.5-2] 2 [0.6] 2 [0.6] 0.54
Symptoms (N,%)
- Abdominal pain 7 7.8% 0 0% 7 9% 0.35
- Diarrhoea 1 1% 0 0 1 1% 0.73
- Haematuria 1 1% 0 0 1 1% 0.73
- Dyspnoea 5 6% 0 0 5 6% 0.44
- Wheeze 3 3% 0 0 3 4% 0.55
- Cough 5 6% 1 11% 4 5% 0.44
- Skin eruptions 10 11% 1 11% 9 11% 1
- Any above listed symptom 32 36% 2 22% 30 37% 0.37
CRP C-reactive protein, ESR erythrocyte sedimentation rate, MCV mean corpuscular volume, N number, WCC white cell count.
Data set was complete for all fields except for ESR and CRP where n = 63 and 79 respectively as outlined in table.
Region of origin was defined according to the United Nations- Composition of macro geographical (continental) regions, geographical sub-regions, and selected
economic and other groupings (http://unstats.un.org/unsd/methods/m49/m49regin.htm#africa).
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purposes.
Nine (10%) had positive helminth serology (either
strongyloides or schistosomiasis). Seven (7.7%) had posi-
tive schistosomiasis serology and 2 (2.2%) had positive
strongyloides serology. No subject had both positive
schistosomiasis and strongyloides serology.Subjects with positive helminth serology were more
likely to have higher eosinophil count (mean [SD]) (0.30
[0.30] versus 0.15 [0.16] ×103cells/mm3, P = 0.021) and
were noted to have lower CD4+ T-cell counts (mean
[SD]) (280 [218] versus 395 [217] cells/mm3, P = 0.08).
Although eosinophil count was significantly higher in
those with positive helminth serology, only 2 out of 9
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sinophil counts above the upper limit of normal (0.4
×109/L).
A single patient with a positive schistosome antibody
only, reported previous treatment for both schistosomia-
sis and strongyloides 20 years earlier in South Africa.
Schistosome antibody positive persons had been resi-
dent in Ireland a median of 5 years. Seven (78%) of those
with positive helminth serology did not report any rele-
vant symptoms that may have been suggestive of an
underlying helminth infection.
Discussion
This is the first study to report the seroprevalence of
schistosomiasis and strongyloides in HIV-infected per-
sons from parasite-endemic regions living in Ireland.
Ten percent of our study cohort had serological evi-
dence of infection with schistosomiasis or strongyloides
at some time. Sixty eight percent of patients in the study
had come to Ireland seeking asylum while 26% had
come for educational purposes.
Similar studies carried out in the United Kingdom re-
port a seroprevalence for schistosomiasis alone of 11-17%
in HIV-infected African immigrants [3,4]. Mascarello
et al. report a prevalence of strongyloides infection alone
of 11% in 138 HIV-infected adults attending an Italian
clinic [5]. Studies carried out in the US looking at hel-
minth infections in general refugee populations have
reported a prevalence of 11-70% [23,24].
Identified prevalence in our cohort may be lower than
that reported in general refugee populations the US as
our patients originated from geographically diverse areas.
The US study reporting very high prevalence of helminth
infections concentrated on refugees from two specific
areas, Somalia and Sudan which may have a greater ex-
posure risk [24].
In addition other studies used a variety of techniques
for identifying infection including direct (where the
parasite is directly visualized by microscopy) and indir-
ect (where a serological marker of parasitic infection
such as antibody is used for diagnosis) methods. Our
study looked at serology alone as a marker of helminth
infection. Positive serology indicates infection at some
time however it does not differentiate between past and
active infection.
Direct methods are the most specific means of
diagnosing active helminth infection however they are
generally regarded as less sensitive as shedding of eggs
may be intermittent if patients have a low parasite
burden and accuracy is dependent on the observer
experience [25,26].
There is some evidence to suggest that HIV-infected
individuals may have an impaired serological response
which may underestimate infection rates, and althoughthis is not a consistent finding it must be considered
when interpreting results in HIV-infected patients [5,27].
Eosinophilia is commonly reported to be associated
with schistosomiasis and strongyloides infection includ-
ing those co-infected with HIV, and may reflect disease
activity and the presence of migrating parasites or ova
[28]. A number of studies have highlighted the fact that
eosinophilia may be absent in helminth infection par-
ticularly if infection is chronic [29].
Only 2 of 9 with a positive helminth serology in our
study had an eosinophil counts exceeding the upper
limit of normal (0.4 × 109/L). A screening approach
based on presence of eosinophilia alone would have
resulted in missed diagnosis in 7 of the 9 patients with
positive helminth serology. In addition, in our study the
CD4+ T-cell count of those identified with eosinophilia
was not significantly different from those with normal eo-
sinophil count (mean [SD] (324 [262] versus 384 [167],
p = 0.37). Presence of eosinophilia has been reported as as-
sociated with low CD4+ T-cell count or low nadir CD4+
T-cell count in HIV infection in other studies [30].
Helminth infections are frequently asymptomatic or
associated with non specific symptoms and may not be
detected unless considered by health care providers and
screened for in individuals with exposure history. We
did not identify any association between symptoms and
positive helminth serology in our study. One of 9 (11%)
patients with positive helminth serology reported any
potential helminth infection-associated symptom while
37% of those with negative helminth serology reported
any symptom.
Increasing evidence suggests that helminth infections
may contribute to complications arising from HIV in-
fection. Schistosome co-infection may lower barriers to
HIV infection, and contribute to more rapid progression
of HIV [31,32]. In addition it has been suggested that
HIV vertical transmission may be more likely in
helminth-infected mothers [33,34]. Further studies are
warranted to clarify these hypotheses, however while
waiting for definitive evidence special emphasis should
be placed on treatment of schistosomiasis and strongy-
loides in areas of increased prevalence particularly in
HIV endemic populations.
Given the potential morbidity and mortality and the
lack of subjective and objective symptoms and signs we
suggest that all individuals from endemic areas, par-
ticularly those with immunocompromising conditions
such as HIV be screened for potential latent parasitic
infections.
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